CLINICAL SIGNIFICANCE OF SUCCESSIVE ESTIMATION OF THE BLOOD CATALASE ACTIVITY IN THE CANCER PATIENT DURING SURGICAL AND ANTI-CANCER DRUG THERAPY.
D000970:Antineoplastic Agents; D001774:Blood Chemical Analysis; D001943:Breast Neoplasms; D002374:Catalase; D004796:Clinical Enzyme Tests; D004358:Drug Therapy; D005770:Gastrointestinal Neoplasms; D006801:Humans; D008099:Liver / Q000201:enzymology*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000453:epidemiology*; D011379:Prognosis; D051381:Rats; D012106:Research; D012509:Sarcoma; D012513:Sarcoma, Experimental; D013964:Thyroid Neoplasms
D000970:Antineoplastic Agents; D002374:Catalase
ANTINEOPLASTIC AGENTS; BLOOD CHEMICAL ANALYSIS; BREAST NEOPLASMS; CATALASE; DRUG THERAPY; ENZYME TESTS; EXPERIMENTAL LAB STUDY; GASTROINTESTINAL NEOPLASMS; LIVER ENZYMOLOGY; NEOPLASM METASTASIS; NEOPLASM STATISTICS; PROGNOSIS; RATS; SARCOMA, EXPERIMENTAL; THYROID NEOPLASMS